Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PDCD1LG2 | Q9BQ51 | 4/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20296354 | 1.00 | CCR5 (0.43) | CCR5HDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL30740137 | 1.00 | CCR5 (0.43) | CCR5HDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL28868640 | 0.89 | CD274 (0.44) | CCR5SYKPDCD1LG2CD274 | |
| SCHEMBL28868545 | 0.82 | ALDH1A1 (0.44) | SYKPDCD1LG2CD274ALDH1A1S1PR1 | |
| SCHEMBL28868541 | 0.82 | ALDH1A1 (0.44) | SYKPDCD1LG2CD274ALDH1A1S1PR1 | |
| SCHEMBL29225552 | 0.78 | ALDH1A1 (0.45) | TSHRALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL30021389 | 0.75 | CYP2D6 (0.49) | ALDH1A1LTA4HKDM4E | |
| SCHEMBL28868539 | 0.75 | ALDH1A1 (0.45) | TSHRCD274ALDH1A1MAPTKDM4E | |
| SCHEMBL28957010 | 0.75 | CD274 (0.36) | PDCD1LG2CD274KDM4EHTT | |
| SCHEMBL3825159 | 0.72 | CCR5 (0.53) | CCR5ALDH1A1KDM4EPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110582493-B | Benzoxazole derivatives as immunomodulators | 因赛特公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| EP-3558985-B1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORP (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-06-23 | — | — | US | disclosed |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-06-23 | — | — | US | disclosed |
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210107900-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
| EP-3558985-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190225601-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-07-25 | — | — | US | disclosed |
| US-20190225601-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-07-25 | — | — | US | disclosed |
| US-10308644-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308644-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2018119266-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2018119266-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | CCR5 98/4885HDAC3 772/4885HDAC4 987/4885 |
| US-20210107900-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CCR5 98/4885HDAC3 772/4885HDAC4 987/4885 |
| US-20190225601-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CCR5 98/4885HDAC3 772/4885HDAC4 987/4885 |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CCR5 98/4885HDAC3 772/4885HDAC4 987/4885 |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | CCR5 98/4885HDAC3 772/4885HDAC4 987/4885 |
| US-10308644-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | CCR5 98/4885HDAC3 772/4885HDAC4 987/4885 |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CCR5 98/4885HDAC3 772/4885HDAC4 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.